US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist
  • 738.000
  • -6.500-0.87%
Close Nov 22 16:00 ET
  • 738.000
  • 0.0000.00%
Post 20:01 ET
81.10BMarket Cap18.25P/E (TTM)

Regeneron Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
15.88%1.29B
-65.38%354M
10.60%1.51B
-8.39%4.59B
-36.64%1.09B
77.18%1.11B
81.15%1.02B
-34.93%1.37B
-29.18%5.01B
-27.51%1.72B
Net income from continuing operations
33.02%1.34B
47.90%1.43B
-11.71%722M
-8.87%3.95B
-3.13%1.16B
-23.40%1.01B
13.65%968.4M
-15.99%817.8M
-46.28%4.34B
-46.29%1.2B
Operating gains losses
-206.06%-134.7M
-1,370.55%-392.6M
17.71%196.1M
623.91%266.4M
27.92%-58.1M
150.10%127M
-81.43%30.9M
-18.53%166.6M
109.51%36.8M
-158.58%-80.6M
Depreciation and amortization
15.46%121.7M
17.07%120.7M
14.67%114.1M
23.32%421M
12.89%113M
13.82%105.4M
38.58%103.1M
33.92%99.5M
19.29%341.4M
34.36%100.1M
Deferred tax
-34.13%-168.6M
43.57%-118.1M
12.06%-190.4M
-12.25%-837.8M
-2.36%-286.3M
-46.67%-125.7M
-34.17%-209.3M
3.78%-216.5M
-407.41%-746.4M
-35.84%-279.7M
Other non cash items
-145.76%-29M
-134.88%-3M
-99.51%100K
-100.02%-100K
-110.36%-17.5M
-119.44%-11.8M
-96.55%8.6M
-75.56%20.6M
-1.00%563M
-44.46%169M
Change In working capital
66.77%-63.9M
-1,017.47%-908.5M
82.86%440.5M
61.32%-94.1M
-116.07%-61.4M
71.18%-192.3M
89.59%-81.3M
-70.74%240.9M
87.30%-243.3M
207.48%382M
-Change in receivables
16.09%-388.9M
-18,200.00%-494.1M
112.66%446.8M
-147.87%-338.8M
-137.66%-82.7M
-19.80%-463.5M
99.16%-2.7M
-82.46%210.1M
136.72%707.8M
137.57%219.6M
-Change in inventory
-112.95%-164.4M
-81.08%-181.8M
-232.91%-155.8M
60.99%-271.7M
67.22%-47.3M
65.46%-77.2M
58.18%-100.4M
47.18%-46.8M
-40.91%-696.5M
11.85%-144.3M
-Change in prepaid assets
191.47%252M
-15,379.41%-526.3M
-1,316.36%-77.9M
19.18%-120.1M
778.61%164.3M
-327.31%-275.5M
98.60%-3.4M
87.72%-5.5M
38.26%-148.6M
-75.43%18.7M
-Change in payables and accrued expense
-66.40%194.4M
415.37%204.6M
-7.14%110.5M
532.51%598.6M
-139.90%-138.7M
460.95%578.6M
152.72%39.7M
147.52%119M
-115.98%-138.4M
-4.95%347.6M
-Change in other working capital
-5.08%43M
714.48%89.1M
425.63%116.9M
16.98%37.9M
172.15%43M
355.93%45.3M
-114.47%-14.5M
-477.89%-35.9M
126.96%32.4M
-21.63%-59.6M
Cash from discontinued investing activities
Operating cash flow
15.88%1.29B
-65.38%354M
10.60%1.51B
-8.39%4.59B
-36.64%1.09B
77.18%1.11B
81.15%1.02B
-34.93%1.37B
-29.18%5.01B
-27.51%1.72B
Investing cash flow
Cash flow from continuing investing activities
-15.74%-574.4M
76.66%-557.2M
-615.78%-1.69B
15.84%-3.19B
96.44%-66.2M
-358.09%-496.3M
-476.69%-2.39B
86.18%-235.7M
29.72%-3.78B
7.70%-1.86B
Capital expenditure reported
-37.44%-241.9M
-59.73%-180.5M
24.86%-133.9M
-21.78%-718.6M
-65.18%-251.4M
-23.51%-176M
26.43%-113M
-25.67%-178.2M
-6.92%-590.1M
1.74%-152.2M
Net PPE purchase and sale
--0
----
----
----
----
--0
----
----
----
----
Net intangibles purchase and sale
--0
-45.45%-30.4M
72.35%-27.9M
79.76%-207.8M
37.90%-62.1M
97.42%-23.9M
---20.9M
---100.9M
---1.03B
---100M
Net business purchase and sale
--0
----
----
76.16%-54.9M
---3.8M
---51.1M
----
----
---230.3M
--0
Net investment purchase and sale
-35.55%-332.5M
83.96%-361.4M
-3,614.52%-1.53B
-13.75%-2.2B
115.64%251.1M
-119.44%-245.3M
-7,410.00%-2.25B
102.78%43.4M
59.91%-1.94B
13.58%-1.61B
Cash from discontinued investing activities
Investing cash flow
-15.74%-574.4M
76.66%-557.2M
-615.78%-1.69B
15.84%-3.19B
96.44%-66.2M
-358.09%-496.3M
-476.69%-2.39B
86.18%-235.7M
29.72%-3.78B
7.70%-1.86B
Financing cash flow
Cash flow from continuing financing activities
-55.66%-634M
22.16%-478.1M
114.60%47.1M
-77.41%-1.79B
-80.17%-446.1M
43.82%-407.3M
-507.52%-614.2M
-598.45%-322.5M
-0.32%-1.01B
72.69%-247.6M
Net common stock issuance
-47.46%-600.6M
22.16%-478.1M
114.60%47.1M
-77.41%-1.79B
-80.17%-446.1M
43.82%-407.3M
-507.52%-614.2M
-598.45%-322.5M
-0.32%-1.01B
72.69%-247.6M
Cash from discontinued financing activities
Financing cash flow
-55.66%-634M
22.16%-478.1M
114.60%47.1M
-77.41%-1.79B
-80.17%-446.1M
43.82%-407.3M
-507.52%-614.2M
-598.45%-322.5M
-0.32%-1.01B
72.69%-247.6M
Net cash flow
Beginning cash position
-1.10%1.93B
-33.57%2.61B
-12.23%2.74B
7.64%3.12B
-38.36%2.16B
-42.80%1.95B
16.96%3.93B
7.64%3.12B
31.30%2.9B
1.74%3.5B
Current changes in cash
-60.70%82.8M
65.57%-681.3M
-115.75%-127.5M
-272.25%-381.2M
249.82%577.4M
119.02%210.7M
-4,105.47%-1.98B
75.54%809.4M
-67.96%221.3M
29.52%-385.4M
Effect of exchange rate changes
500.00%800K
25.00%-300K
---500K
---400K
--200K
---200K
---400K
--0
--0
--0
End cash Position
-6.87%2.01B
-1.10%1.93B
-33.57%2.61B
-12.23%2.74B
-12.23%2.74B
-38.36%2.16B
-42.80%1.95B
16.96%3.93B
7.64%3.12B
7.64%3.12B
Free cash flow
14.75%1.05B
-83.89%143.1M
24.09%1.35B
7.93%3.67B
-47.11%776.2M
307.63%914.4M
116.29%888.5M
-44.46%1.09B
-47.96%3.4B
-33.82%1.47B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 15.88%1.29B-65.38%354M10.60%1.51B-8.39%4.59B-36.64%1.09B77.18%1.11B81.15%1.02B-34.93%1.37B-29.18%5.01B-27.51%1.72B
Net income from continuing operations 33.02%1.34B47.90%1.43B-11.71%722M-8.87%3.95B-3.13%1.16B-23.40%1.01B13.65%968.4M-15.99%817.8M-46.28%4.34B-46.29%1.2B
Operating gains losses -206.06%-134.7M-1,370.55%-392.6M17.71%196.1M623.91%266.4M27.92%-58.1M150.10%127M-81.43%30.9M-18.53%166.6M109.51%36.8M-158.58%-80.6M
Depreciation and amortization 15.46%121.7M17.07%120.7M14.67%114.1M23.32%421M12.89%113M13.82%105.4M38.58%103.1M33.92%99.5M19.29%341.4M34.36%100.1M
Deferred tax -34.13%-168.6M43.57%-118.1M12.06%-190.4M-12.25%-837.8M-2.36%-286.3M-46.67%-125.7M-34.17%-209.3M3.78%-216.5M-407.41%-746.4M-35.84%-279.7M
Other non cash items -145.76%-29M-134.88%-3M-99.51%100K-100.02%-100K-110.36%-17.5M-119.44%-11.8M-96.55%8.6M-75.56%20.6M-1.00%563M-44.46%169M
Change In working capital 66.77%-63.9M-1,017.47%-908.5M82.86%440.5M61.32%-94.1M-116.07%-61.4M71.18%-192.3M89.59%-81.3M-70.74%240.9M87.30%-243.3M207.48%382M
-Change in receivables 16.09%-388.9M-18,200.00%-494.1M112.66%446.8M-147.87%-338.8M-137.66%-82.7M-19.80%-463.5M99.16%-2.7M-82.46%210.1M136.72%707.8M137.57%219.6M
-Change in inventory -112.95%-164.4M-81.08%-181.8M-232.91%-155.8M60.99%-271.7M67.22%-47.3M65.46%-77.2M58.18%-100.4M47.18%-46.8M-40.91%-696.5M11.85%-144.3M
-Change in prepaid assets 191.47%252M-15,379.41%-526.3M-1,316.36%-77.9M19.18%-120.1M778.61%164.3M-327.31%-275.5M98.60%-3.4M87.72%-5.5M38.26%-148.6M-75.43%18.7M
-Change in payables and accrued expense -66.40%194.4M415.37%204.6M-7.14%110.5M532.51%598.6M-139.90%-138.7M460.95%578.6M152.72%39.7M147.52%119M-115.98%-138.4M-4.95%347.6M
-Change in other working capital -5.08%43M714.48%89.1M425.63%116.9M16.98%37.9M172.15%43M355.93%45.3M-114.47%-14.5M-477.89%-35.9M126.96%32.4M-21.63%-59.6M
Cash from discontinued investing activities
Operating cash flow 15.88%1.29B-65.38%354M10.60%1.51B-8.39%4.59B-36.64%1.09B77.18%1.11B81.15%1.02B-34.93%1.37B-29.18%5.01B-27.51%1.72B
Investing cash flow
Cash flow from continuing investing activities -15.74%-574.4M76.66%-557.2M-615.78%-1.69B15.84%-3.19B96.44%-66.2M-358.09%-496.3M-476.69%-2.39B86.18%-235.7M29.72%-3.78B7.70%-1.86B
Capital expenditure reported -37.44%-241.9M-59.73%-180.5M24.86%-133.9M-21.78%-718.6M-65.18%-251.4M-23.51%-176M26.43%-113M-25.67%-178.2M-6.92%-590.1M1.74%-152.2M
Net PPE purchase and sale --0------------------0----------------
Net intangibles purchase and sale --0-45.45%-30.4M72.35%-27.9M79.76%-207.8M37.90%-62.1M97.42%-23.9M---20.9M---100.9M---1.03B---100M
Net business purchase and sale --0--------76.16%-54.9M---3.8M---51.1M-----------230.3M--0
Net investment purchase and sale -35.55%-332.5M83.96%-361.4M-3,614.52%-1.53B-13.75%-2.2B115.64%251.1M-119.44%-245.3M-7,410.00%-2.25B102.78%43.4M59.91%-1.94B13.58%-1.61B
Cash from discontinued investing activities
Investing cash flow -15.74%-574.4M76.66%-557.2M-615.78%-1.69B15.84%-3.19B96.44%-66.2M-358.09%-496.3M-476.69%-2.39B86.18%-235.7M29.72%-3.78B7.70%-1.86B
Financing cash flow
Cash flow from continuing financing activities -55.66%-634M22.16%-478.1M114.60%47.1M-77.41%-1.79B-80.17%-446.1M43.82%-407.3M-507.52%-614.2M-598.45%-322.5M-0.32%-1.01B72.69%-247.6M
Net common stock issuance -47.46%-600.6M22.16%-478.1M114.60%47.1M-77.41%-1.79B-80.17%-446.1M43.82%-407.3M-507.52%-614.2M-598.45%-322.5M-0.32%-1.01B72.69%-247.6M
Cash from discontinued financing activities
Financing cash flow -55.66%-634M22.16%-478.1M114.60%47.1M-77.41%-1.79B-80.17%-446.1M43.82%-407.3M-507.52%-614.2M-598.45%-322.5M-0.32%-1.01B72.69%-247.6M
Net cash flow
Beginning cash position -1.10%1.93B-33.57%2.61B-12.23%2.74B7.64%3.12B-38.36%2.16B-42.80%1.95B16.96%3.93B7.64%3.12B31.30%2.9B1.74%3.5B
Current changes in cash -60.70%82.8M65.57%-681.3M-115.75%-127.5M-272.25%-381.2M249.82%577.4M119.02%210.7M-4,105.47%-1.98B75.54%809.4M-67.96%221.3M29.52%-385.4M
Effect of exchange rate changes 500.00%800K25.00%-300K---500K---400K--200K---200K---400K--0--0--0
End cash Position -6.87%2.01B-1.10%1.93B-33.57%2.61B-12.23%2.74B-12.23%2.74B-38.36%2.16B-42.80%1.95B16.96%3.93B7.64%3.12B7.64%3.12B
Free cash flow 14.75%1.05B-83.89%143.1M24.09%1.35B7.93%3.67B-47.11%776.2M307.63%914.4M116.29%888.5M-44.46%1.09B-47.96%3.4B-33.82%1.47B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Infectious Disease
Infectious Disease
Intraday+0.43%